Hepatology

Article	Citations
Acute encephalopathy without hyperammonemia has a different presentation than overt HE and displays a similarly severe prognosis	1921
Reply: Fiber and whole grain intakes in relation to liver cancer risk—An analysis in 2 prospective cohorts and systematic review and meta-analysis of prospective studies	1672
Multi-omics approaches for identifying the PANoptosis signature and prognostic model via a multimachine-learning computational framework for intrahepatic cholangiocarcinoma	1502
Regulatory role and translational potential of CCL11 in liver fibrosis	977
Higher level of HBsAg associated with delayed development of HCC in immune-tolerant patients	400
Stellate cell-specific adhesion molecule protocadherin 7 regulates sinusoidal contraction	307
Comparison of pharmacological therapies in metabolic dysfunction–associated steatohepatitis for fibrosis regression and MASH resolution: Systematic review and network meta-analysis	233
ZNT1 and Zn2+ control TLR4 and PD-L1 endocytosis in macrophages to improve chemotherapy efficacy against liver tumor	223
Precipitous changes in nomenclature and definitions—NAFLD becomes SLD: Implications for and expectations of AASLD journals	216
Letter to the Editor: LO2, a misidentified cell line: Some data should be interpreted with caution	215
Letter to the editor: Targeted decrease of portal hepatic pressure gradient immediately after TIPS improves ascites control and prognosis	214
More immunosuppressive, more immunotherapy responsive? A double-edged sword of HBV-induced immune response in HCC	201
Letter to the Editor: Regarding terlipressin-related patient outcomes in hepatorenal syndrome-acute kidney injury	186
Reply: Medications promoting abstinence in alcohol-associated cirrhosis	180
Late-Breaking Abstracts	178
Plasma proteomic signature of fatty liver disease: The Rotterdam Study	177
Post-vax vein vigilance: Unmasking splanchnic thrombosis risks	173
Boosting Success: Optimizing Thiopurine Therapy in Autoimmune Hepatitis With Allopurinol	166
Letter to the Editor: The Hepa 1–6 may not be suitable for use in hepatocellular carcinoma models to explore responses to drug therapy	164
Switch‐associated protein 70 protects against nonalcoholic fatty liver disease through suppression of TAK1	163
Letter to the editor: Beneath the surface of the pandemic: Persons with alcohol‐associated liver disease need our attention	145
Cover Image	143
Alan Hofmann (1931‐2021): A career well spent understanding bile acids	141
Retracted: M2 Macrophage–Derived Exosomes Facilitate HCC Metastasis by Transferring αMβ2 Integrin to Tumor Cells	133
Requirement of RORα for maintenance and antitumor immunity of liver‐resident natural killer cells/ILC1s	132

Letter to the editor: Treatment options for 3–5‐cm solitary HCC—Need a closer look!	128
Letter to the editor: The precise relationship between MELD and survival without a liver transplant	127
Letter to the editor: The role of aquaporin 9 in modeling of ornithine transcarbamylase deficiency	127
Letter to the Editor: Real-world evidence supports nephrotoxic risk of anakinra plus zinc in alcohol-associated hepatitis	125
Changing epidemiology of hepatocellular cancer in the United States: Winning the battle but it is not over yet	124
Moving beyond the liver—Proteomics as a molecular footprint of systemic damage in metabolic dysfunction–associated steatotic liver disease	119
Reply	111
Hepatic encephalopathy—We are no longer those who believe that reality is what we perceive	111
Reply: Can pFIB scores reliably exclude significant liver fibrosis in pediatric MASLD?	111
Letter to the Editor: Insurance should cover vancomycin for primary sclerosing cholangitis	110
Retraction: GABA induces the differentiation of small into large cholangiocytes by activation of Ca2+/CaMK I-dependent adenylyl cyclase 8	109
Biopsy-free endpoints in MASH trials: A comparative look at MASHResInd and FAST	109
PGD2/DP1 axis promotes liver regeneration by secreting Wnt2 in KCs in mice	108
Effectiveness and safety of glecaprevir/pibrentasvir for 8 weeks in the treatment of patients with acute hepatitis C: A single-arm retrospective study	105
Honey, I shrunk the tumor: Downstaging HCC before liver transplantation	105
Reply: Liver stiffness progression comparison between diabetics and non-diabetics with biopsy-proven metabolic dysfunction–associated steatosis	104
Access to technology to support telehealth in areas without specialty care for liver disease	101
Efficacy and safety of infliximab in patients with autoimmune hepatitis	100
Validation and expansion of Baveno VII criteria for cACLD and CSPH based on liver stiffness and platelet count: Correlation with risk of hepatic decompensation and death	95
Dysregulation of RalA signaling through dual regulatory mechanisms exerts its oncogenic functions in hepatocellular carcinoma	93
Group‐2 Innate Lymphoid Cells Promote HCC Progression Through CXCL2‐Neutrophil‐Induced Immunosuppression	92
Implementation of a controlled human infection model for evaluation of HCV vaccine candidates	92
AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease	90
NOD‐like receptor protein 3 activation causes spontaneous inflammation and fibrosis that mimics human NASH	90
Hepatocyte‐specific deletion of adipose triglyceride lipase (adipose triglyceride lipase/patatin‐like phospholipase domain containing 2) ameliorates dietary induced steatohepatitis in mice	89
	88
Letter to the Editor: Comparative efficacy of pharmacologic therapies for MASH in reducing liver fat content—Systematic review and network meta-analysis	87
	87
Letter to the Editor: Learning more about the safety of atezolizumab plus bevacizumab in patients with hepatocellular carcinoma	87
The relationship between mean arterial pressure and terlipressin in hepatorenal syndrome-acute kidney injury reversal: A post hoc analysis	86
Deciphering the spatial tumor microenvironment in intrahepatic cholangiocarcinoma	86
Erratum: AASLD Practice Guidance on Acute-on-chronic liver failure and the management of critically ill patients with cirrhosis	86
Refinement of histologic subtypes and identification of biomarkers linked to unfavorable prognosis in cholangiocarcinoma: The ENSCCA registries’ framework for digital twin advancement	85
Reply	85
Reply: Is fecal acetate a viable pan-etiological predictor of outcomes in HCC immunotherapy?	83
Reply: The CRAPT-M score: Robust enough for clinical practice?	82
Interleukin 8-CXCR2–mediated neutrophil extracellular trap formation in biliary atresia associated with neutrophil extracellular trap–induced stellate cell activation	81
Metabolic dysfunction-associated steatotic liver disease and the heart	81
In vivo imaging of calcium dynamics in zebrafish hepatocytes	80
Tumor-derived CCL2 drives tumor growth and immunosuppression in IDH1-mutant cholangiocarcinoma	80
Divergent trends in cirrhosis and liver cancer highlight the ongoing efforts required for hepatitis elimination	80
The spectrum of primary liver cancers: heterogeneity and continuity. A foundation for diagnosis and treatment of cancer	79
Healthy peribiliary glands are necessary for successful liver transplantation	78
Synergistic combination of cytotoxic chemotherapy and cyclin‐dependent kinase 4/6 inhibitors in biliary tract cancers	78
Letter to the editor: Is PAI‐1 a thrombotic biomarker in NASH cirrhosis?	78
Instructions to Authors	78
Hepatology Highlights	77
Letter to the editor	77
Letter to the editor: Regression of liver fibrosis after bariatric operations: A glass two‐third full rather than half empty	77
Erratum	76

The digital determinants of liver disease	75
Letter to the Editor: Enhancing the rigor and impact of cholangiocarcinoma research: Addressing key concerns in the PTPN9-FGFR2 interaction study	74
Use of noninvasive scores to predict hepatic steatosis: Flaws and caveats	73
Solving the puzzle of fibrosis resolution in alcohol-associated liver disease: An insight from KDM5 demethylases and LXR activation	72
Erratum: Identification and characterization of a hepatic IL-13–producing ILC3-like population potentially involved in liver fibrosis	71
Understanding advanced cystic fibrosis liver disease through genetic variation: Where do the pathways lead and how much further must we go?	71
5S rRNA pseudogene transcripts are associated with interferon production and inflammatory responses in alcohol-associated hepatitis	71
Letter to the Editor: Overlooking the important factor: Hypoxia	70
Reply: How does bile acid–induced IRF3 phosphorylation mediate cholestatic liver and kidney injury?—More needs to be known	69
Reply: Several issues to consider in the study of hepatocellular carcinoma progression mechanism	69
Letter to the Editor : Insights into Immune-Mediated adverse events and survival outcomes : Lessons from HIMALAYA	68
Clinical decision support and electronic interventions to improve care quality in chronic liver diseases and cirrhosis	68
Much more needed in natural history of Alagille syndrome	67
Reply: Diabetes and fibrosis: Parallel risks or overlap?	67
CD44 in myEloid cells is a major driver of liver inflammation and injury in alcohol-related liver disease	67
Dedifferentiation‐associated inflammatory factors of long‐term expanded human hepatocytes exacerbate their elimination by macrophages during liver engraftment	67
Letter to the Editor: Hepatic decompensation is the major driver of mortality in hepatocellular carcinoma patients treated with atezolizumab plus bevacizumab: The impact of successful antiviral treatm	67
Erratum: Effects of trientine and penicillamine on intestinal copper uptake: A mechanistic 64Cu PET/CT study in healthy humans	66
Therapeutic manipulation of the microbiome in liver disease	65
Genes that fit just right: Unzipping the genome of fatty liver disease	65
Bariatric surgery for metabolic dysfunction-associated steatotic liver disease (MASLD): Current knowledge of mechanisms	63
Letter to the Editor: Primary sclerosing cholangitis and autoimmune hepatitis—Distinct or common autoimmune penetrance?	63
Letter to the Editor: Screening and risk stratification disparities in hispanic MASLD	63
Emergence of highly profibrotic and proinflammatory Lrat + Fbln2 + HSC subpopulation in alcoholic hepatitis	62
With Alcohol as the Fuel, COVID Is the Match: Liver Transplantation for Alcohol‐Associated Liver Disease Is Increasing in the United States	62
Effect of tenofovir-based HIV pre-exposure prophylaxis against HBV infection in men who have sex with men	62
Magnetic resonance elastography for prediction of long‐term progression and outcome in chronic liver disease: A retrospective study	62
The international quest for the imaging diagnosis of liver cancer	62
A strategy of vascular‐targeted therapy for liver fibrosis	62
NAFLD‐related hepatocellular carcinoma: The growing challenge	62
Outcomes of pregnancy in autoimmune hepatitis: A population‐based study	61
Hepatocellular carcinomas, exhibiting intratumor fibrosis, express cancer-specific extracellular matrix remodeling and WNT/TGFB signatures, associated with poor outcome	61
NASHFit: A randomized controlled trial of an exercise training program to reduce clotting risk in patients with NASH	61
Fontan‐associated liver disease	60
Circulating TREM2 as a noninvasive diagnostic biomarker for NASH in patients with elevated liver stiffness	59
Immunobiology of primary sclerosing cholangitis	59
Stard1 promotes cholestatic liver injury and disease progression by sensitizing to bile acid hepatotoxicity	59
Computational drug prediction in hepatoblastoma by integrating pan-cancer transcriptomics with pharmacological response	59
National prevalence estimates for steatotic liver disease and subclassifications using consensus nomenclature	58
The clot and the complicated consult	58
Pathway to global elimination of hepatitis B: HBV cure is just the first step	57
Letter to the Editor: Statins as potential confounding factors to investigate the association between the use of GLP-1 receptor agonists and risk of HCC	57
Determining safe washout period for immune checkpoint inhibitors prior to liver transplantation: An international retrospective cohort study	57
Letter to the Editor: Peripheral Foxp3-high Tregs as a dual biomarker for HCC prognosis and immunotherapy response	55
Serum amyloid A1–induced intrahepatic regulatory T-cell dysfunction drives autoimmune hepatitis progression	55
The role of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in managing metabolic dysfunction–associated steatotic liver disease	55
Bile metabolic fingerprints distinguish biliary tract cancer from benign biliary diseases	55
Natural history and development of a novel composite endpoint in patients with alcohol-associated Hepatitis: Data from a prospective multicenter study	55
Integrative hepatology: Enhancing overall health to manage liver disease	54
Unraveling bidirectional evolution of unstable mitochondrial DNA mutations in hepatocellular carcinoma at single-cell resolution	54
Letter to Editor: Considerations on the specific role of LHX2 in the process of hepatic stellate cells regulating hepatocyte function	53
Cell therapies and liver organogenesis technologies: Promising strategies for end-stage liver disease	53
The “shell game” after objective response in patients with advanced HCC treated with immunotherapy	52
Letter to the Editor: Exchangeable copper in the Danish cohort of patients with Wilson disease	52
Letter to the Editor: Can pFIB scores reliably exclude significant liver fibrosis in pediatric MASLD?	52
HEAR-MHE study: Automated speech analysis identifies minimal hepatic encephalopathy and may predict future overt hepatic encephalopathy	51
Clonal hematopoiesis of indeterminate potential and risk of hepatocellular carcinoma: New kids on the block	51
Letter to the editor: Considerations on the use of the liver transplant comorbidity index (LTCI)	51
Optimizing thiopurine therapy in autoimmune hepatitis: A multicenter study on monitoring metabolite profiles and co-therapy with allopurinol	51
Reply	50
SERPINA12 promotes the tumorigenic capacity of HCC stem cells through hyperactivation of AKT/β-catenin signaling	50
Reply	50
Reply	50
Letter to the Editor: Association between birth weight, preterm birth, and nonalcoholic fatty liver disease in a community-based cohort	50
Manuscript best practices: Takeaways from a community conversation	50
Erratum: Inhibition of microRNA-24 expression in liver prevents hepatic lipid accumulation and hyperlipidemia	50
Oral Abstracts	49
Malignant progression of liver cancer progenitors requires lysine acetyltransferase 7–acetylated and cytoplasm‐translocated G protein GαS	49
Reply	49
Letter to the Editor: Acute rejection after liver transplantation with machine perfusion versus static cold storage: A systematic review and meta-analysis	49
Hepatology Highlights	48
Letter to the editor: RECAM for the diagnosis of DILI—Is it time to incorporate additional pharmacological criteria?	48
Reply	47
A Simple Bacterium Links Heart Infection to Inflammatory Liver Disease	47
Racial and ethnic disparities in early treatment with immunotherapy for advanced HCC in the United States	47
Downstaging of hepatocellular carcinoma before liver transplantation: Results from a national multicenter prospective cohort study	47
Letter to the Editor: NAFLD, MAFLD or MASLD? Cut the Gordian knot with “Ludwig disease”	47
Benefits and challenges to therapeutic targeting of bile acid circulation in cholestatic liver disease	47
REPLY:	47
HNF4α-CDKL3 axis restricts MASLD progression by targeting FoxO1 via noncanonical phosphorylation	47

Hepatic GDP-fucose transporter SLC35C1 attenuates cholestatic liver injury and inflammation by inducing CEACAM1 N153 fucosylation	46
Letter to the editor: Preliminary evidence of safety and tolerability of atezolizumab plus bevacizumab in patients with hepatocellular carcinoma and Child‐Pugh A and B cirrhosis: A real‐world study—Sh	46
Platelet-derived mitochondria regulate lipid metabolism in nonalcoholic steatohepatitis through extracellular vesicles	46
Acute rejection after liver transplantation with machine perfusion versus static cold storage: A systematic review and meta-analysis	45
E. coli and the etiology of human PBC: Antimitochondrial antibodies and spreading determinants	45
Reply: Regarding the use of decision curve analysis in predicting long-term complications of liver cirrhosis	45
Early detection of primary liver cancer using plasma cell‐free DNA fragmentomics: Do all the pieces come together?	45
CAFs shape myeloid‐derived suppressor cells to promote stemness of intrahepatic cholangiocarcinoma through 5‐lipoxygenase	45
Distinct structural and dynamic components of portal hypertension in different animal models and human liver disease etiologies	45
Preliminary evidence of safety and tolerability of atezolizumab plus bevacizumab in patients with hepatocellular carcinoma and Child‐Pugh A and B cirrhosis: A real‐world study	45
Letter to the Editor: Cautious interpretation of the association between finite treatment and better prognosis in initially HBeAg-negative hepatitis B patients with cirrhosis	45
PNPLA3 rs738409 and risk of fibrosis in NAFLD: Exploring mediation pathways through intermediate histological features	45
The outcome of boosting mitochondrial activity in alcohol-associated liver disease is organ-dependent	44
Telehealth interventions in patients with chronic liver diseases: A systematic review	44
Future directions in acute liver failure	44
Tertiary lymphoid structures in HCC: Influence on immune cell profiles in tumors and on efficacy of adjuvant PD-1 inhibitor therapy after hepatectomy	44
Reply: Quality indicators and the safety profile of endoscopic intervention in patients with bleeding esophageal varices	44
More than a lark? LRRK2 inhibitors to treat alpha-1 antitrypsin deficiency	43
Reply: Development and validation of pFIB scores for exclusion of significant liver fibrosis in pediatric MASLD	43
Prevalence of subclinical hypothyroidism and longitudinal thyroid-stimulating hormone changes in youth with metabolic dysfunction–associated steatotic liver disease: An observational study	43
Predicting liver outcomes with biomarker monitoring in MASLD	43
Prognostic significance of mild ascites in patients with cirrhosis	43
Letter to the editor: Re-examining neoadjuvant chemoradiation plus transplantation versus liver resection for de novo perihilar cholangiocarcinoma	43
Reduction of Z alpha-1 antitrypsin polymers in human iPSC-hepatocytes and mice by LRRK2 inhibitors	43
Fine-tuning of hepatitis C virus immune evasion through hypervariable region 1 insertions	42
Intrahepatic cholangiocarcinoma PANoptosidy	42
Letter to the editor: Is NAFLD a bystander or contributor to coronary artery disease?	41
Early screening, diagnosis and recurrence monitoring of hepatocellular carcinoma in patients with chronic hepatitis B based on serum N-glycomics analysis: A cohort study	41
Lean NAFLD is associated with adverse liver events and mortality: Moving beyond BMI	41
Masthead	41
Development and validation of a risk prediction model for patients with hepatocellular carcinoma receiving atezolizumab–bevacizumab	41
Dissecting the liver inflammation ecosystem identifies annexin A1 as a pro-resolving target for liver failure	41
Letter to the Editor: Is right heart assessment vital for evaluating terlipressin-related outcomes in hepatorenal syndrome-acute kidney injury?	41
Imaging for better responses to immunotherapy in hepatocellular carcinoma	40
Letter to the Editor: More questions than answers—Response to the POP-NEXT project	40
Reply: The associations between hepatic steatosis and incident cardiovascular disease and all-cause mortality	40
Letter to the Editor: NAFLD/MAFLD: One size does not fit all, certainly not for children!	40
Letter to the Editor: Influence of liver stiffness heterogeneity on staging fibrosis in patients with nonalcoholic fatty liver disease	40
Reply: Machine learning models for NAFLD/NASH and cirrhosis diagnosis and staging: accuracy and routine variables are the success keys	40
What is in a name? Toward culturally sensitive nomenclature for liver disease in the east and west	40
Letter to the editor: HuR in liver homeostasis	40
Corticosteroids for high‐grade immune checkpoint inhibitor–mediated hepatitis: Is less more?	39
Letter to the Editor: There may be a misunderstanding about the function of circular RNA as miRNA sponges	39
Cover Image	39
Letter to the editor: Relevance of population‐based cutoffs to define frailty in clinical studies	39
Letter to the Editor: Scavenger receptor a is a major homeostatic regulator that restrains drug-induced liver injury	39
Table of contents	38
Letter to the editor: High rate of clinical and immunological response in patients with HCV‐associated cryoglobulinemia	38
Reply	38
Reply	38
Masthead	38
Diverse facets of MDSC in different phases of chronic HBV infection: Impact on HBV‐specific T‐cell response and homing	38
Erratum for Ren, H et al. Sirtuin 2 prevents liver steatosis and metabolic disorders by deacetylation of hepatocyte nuclear factor 4α	38
Table of contents	38
Presenting the new incoming editorial team for hepatology: Team members and perspectives	38
Multicentered study of patient outcomes after declined for early liver transplantation in severe alcohol-associated hepatitis	38
Effect of phospholipid curcumin Meriva on liver histology and kidney disease in nonalcoholic steatohepatitis: A randomized, double-blind, placebo-controlled trial	37
Letter to the Editor: Survival benefit of transarterial chemoembolization combined with tyrosine kinase and immune checkpoint inhibitors as conversion therapy for unresectable hepatocellular carcinoma	37
Antiviral therapy substantially reduces HCC risk in patients with chronic hepatitis B infection in the indeterminate phase	37
Neoadjuvant and adjuvant therapy for biliary tract cancer: Advances and limitations	37
Reply: Can plasma FSTL-1 levels serve as a reliable biomarker for advanced fibrosis?	37
Hepatocyte‐derived MASP1‐enriched small extracellular vesicles activate HSCs to promote liver fibrosis	37
Letter to the Editor: Key advance in noninvasive fibrosis assessment: Evidence from China	37
Clinicogenomic characteristics and synthetic lethal implications of germline homologous recombination‐deficient hepatocellular carcinoma	37
Gut microbiome features associated with liver fibrosis in Hispanics, a population at high risk for fatty liver disease	36
Evaluating the risk-benefit ratio of immunotherapy according to liver-functional reserve in advanced HCC: the dark side of the moon	36
An integrated analysis of fecal microbiome and metabolomic features distinguish non-cirrhotic NASH from healthy control populations	36
A global action agenda for turning the tide on fatty liver disease	36
A genome-wide association study identified PTPN2 as a population-specific susceptibility gene locus for primary biliary cholangitis	35
Tripartite motif‐containing protein 31 confers protection against nonalcoholic steatohepatitis by deactivating mitogen‐activated protein kinase kinase kinase 7	35
Breakthrough SARS‐CoV‐2 infection outcomes in vaccinated patients with chronic liver disease and cirrhosis: A National COVID Cohort Collaborative study	35
Pseudouridine synthase 1 promotes hepatocellular carcinoma through mRNA pseudouridylation to enhance the translation of oncogenic mRNAs	35
Performance of American Gastroenterological Association Clinical Care Pathway for the risk stratification of patients with nonalcoholic fatty liver disease in the US population	35
Serum biomarkers correlated with liver stiffness assessed in a multicenter study of pediatric cholestatic liver disease	35
Cost-effectiveness of MRE versus VCTE in staging fibrosis for nonalcoholic fatty liver disease (NAFLD) patients with advanced fibrosis	35
The macrophage STING-YAP axis controls hepatic steatosis by promoting the autophagic degradation of lipid droplets	35
The evolving role of liver sinusoidal endothelial cells in liver health and disease	35
Neutrophil extracellular traps promote MASH fibrosis by metabolic reprogramming of HSC	34
Association of hepatitis delta virus with liver morbidity and mortality: A systematic literature review and meta-analysis	34
BileMet: A new frontier in distinguishing malignant from benign biliary conditions	34
Single-cell dissection of the multicellular ecosystem and molecular features underlying microvascular invasion in HCC	34
Category Index	34
Letter to the editor: Loss of Sam50 in hepatocytes induces cardiolipin‐dependent mitochondrial membrane remodeling to trigger mtDNA release and liver injury	34
A multidisciplinary approach to the diagnosis and management of Wilson disease: Executive summary of the 2022 Practice Guidance on Wilson disease from the American Association for the Study of Liver D	34
Category Index	34
Letter to the Editor: Use of HBV RNA and to predict change in serological status and disease activity in CHB	34
Feasibility of hepatitis C elimination by screening and treatment alone in high-income countries	33
Benefit and harm of waiting time in liver transplantation for HCC	33
RIPPLY1 suppresses cancer cell stemness via targeting TBX19 in CTNNB1-mutated hepatocellular carcinoma	33
Dynamic duo: Spleen stiffness and bilirubin revolutionize PSVD screening	33
An international survey on patterns of practice in NAFLD and expectations for therapies—The POP‐NEXT project	33
Reply to the Letter to the Editor: Revisiting FOXP3 expression and its prognostic implications in hepatocellular carcinoma	33
The MASTL/YBX1/PAK4 axis regulated by stress-activated STK24 triggers lenvatinib resistance and tumor progression in HCC	32
Reply: Reevaluating PCA and SCTransform usage in single-cell intrahepatic cholangiocarcinoma analysis	32
HDV RNA and liver disease progression: What do we know?	32